The role of SGLT, NHE, and their inhibitors in diabetes and... | Download Scientific Diagram
SGLT-2-Hemmer zur Diabetes-Behandlung
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control | Nature Reviews Cardiology
Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently | SpringerLink
SGLT2-Inhibitoren zur Therapie des Typ-2-Diabetes
SGLT-1/2-Hemmer auch bei Typ-1-Diabetes? - Der niedergelassene Arzt
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis - The Lancet Diabetes & Endocrinology
IJMS | Free Full-Text | SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
Typ-2-Diabetes: Wirkmechanismus der SGLT-2-Hemmer entschlüsselt
Diabetes – SGLT2 Inhibitor - Sirona Biochem
News
JCM | Free Full-Text | SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure—A Concise Review
PharmaWiki - SGLT2-Hemmer
Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects - Journal of Molecular and Cellular Cardiology
Diabetes wird kardiologisch - DER PRIVATARZT DIGITAL
SGLT-2 and the genesis of hyperfiltration - Renal Fellow Network
SGLT2-Inhibitoren zur Therapie des Typ-2-Diabetes
Bayerisches Ärzteblatt
SGLT2 Inhibitors – Diabetologia
The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes - ScienceDirect
Carbohydrates in medicines (SGLT-2 inhibitors for the treatment of type 2 diabetes mellitus)
BVKD – Die Diabetes-Kliniken - Ketoazidose unter SGLT2-Blockern • diabetologie-online
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial -
EMA und FDA sind uneins | PZ – Pharmazeutische Zeitung
SGLT2 Inhibitors: The Future is Flozin! | BROWN MED-PEDS RESIDENCY
Neue Diabetemedikamente Typ-2-Diabetes - diabetes-news : diabetes-news
